Perceptive Advisors as of Dec. 31, 2011
Portfolio Holdings for Perceptive Advisors
Perceptive Advisors holds 66 positions in its portfolio as reported in the December 2011 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Pharmasset | 13.4 | $58M | 452k | 128.20 | |
| Celgene Corporation | 11.2 | $49M | 721k | 67.60 | |
| Ariad Pharmaceuticals | 8.7 | $38M | 3.1M | 12.25 | |
| Neurocrine Biosciences (NBIX) | 6.5 | $28M | 3.3M | 8.50 | |
| Allergan Inc Com Stk | 6.1 | $26M | 300k | 87.74 | |
| Aegerion Pharmaceuticals | 4.8 | $21M | 1.3M | 16.74 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 4.8 | $21M | 627k | 32.91 | |
| Seattle Genetics | 3.2 | $14M | 820k | 16.72 | |
| Shire | 3.0 | $13M | 126k | 103.90 | |
| Repros Therapeutics | 2.6 | $11M | 2.3M | 4.82 | |
| Endo Pharmaceuticals | 2.5 | $11M | 312k | 34.53 | |
| Capital Senior Living Corporation | 2.4 | $10M | 1.3M | 7.94 | |
| Novartis (NVS) | 2.2 | $9.7M | 170k | 57.17 | |
| Amgen | 2.2 | $9.5M | 148k | 64.21 | |
| Medivation | 2.1 | $9.2M | 201k | 46.11 | |
| Biogen Idec (BIIB) | 1.8 | $7.7M | 70k | 110.06 | |
| Mylan | 1.6 | $6.9M | 320k | 21.46 | |
| Trius Therapeutics | 1.5 | $6.6M | 921k | 7.15 | |
| Neptune Technologies Bioreso | 1.5 | $6.4M | 2.7M | 2.36 | |
| Thoratec Corporation | 1.4 | $6.3M | 187k | 33.56 | |
| AVI BioPharma ComStk Usd0.0001 | 1.0 | $4.3M | 5.8M | 0.74 | |
| Array BioPharma | 1.0 | $4.2M | 1.9M | 2.16 | |
| WellPoint | 0.9 | $4.0M | 60k | 66.25 | |
| Hospira | 0.9 | $3.9M | 128k | 30.37 | |
| Regeneron Pharmaceuticals (REGN) | 0.8 | $3.3M | 60k | 55.43 | |
| Express Scripts | 0.7 | $3.1M | 70k | 44.69 | |
| NPS Pharmaceuticals | 0.7 | $3.1M | 475k | 6.59 | |
| Pharmacyclics | 0.7 | $3.0M | 202k | 14.82 | |
| Human Genome Sciences | 0.7 | $3.0M | 400k | 7.39 | |
| Perrigo Company | 0.7 | $2.9M | 30k | 97.30 | |
| Medtronic | 0.7 | $2.9M | 75k | 38.25 | |
| Gilead Sciences (GILD) | 0.6 | $2.7M | 66k | 40.93 | |
| Targacept | 0.6 | $2.5M | 450k | 5.57 | |
| Athersys | 0.6 | $2.5M | 1.5M | 1.73 | |
| Optimer Pharmaceuticals | 0.6 | $2.4M | 200k | 12.24 | |
| Onyx Pharmaceuticals | 0.5 | $2.1M | 48k | 43.96 | |
| Chelsea Therapeutics International | 0.5 | $2.1M | 400k | 5.13 | |
| Progenics Pharmaceuticals | 0.4 | $1.7M | 201k | 8.54 | |
| EXACT Sciences Corporation (EXAS) | 0.4 | $1.6M | 200k | 8.12 | |
| Keryx Biopharmaceuticals | 0.3 | $1.5M | 600k | 2.53 | |
| Dendreon Corporation | 0.3 | $1.5M | 200k | 7.60 | |
| Cutera | 0.3 | $1.4M | 185k | 7.45 | |
| Response Genetics (RGDXQ) | 0.3 | $1.4M | 913k | 1.53 | |
| Neostem (NBS) | 0.3 | $1.3M | 2.6M | 0.51 | |
| Transcept Pharmaceuticals | 0.3 | $1.2M | 159k | 7.84 | |
| Cell Therapeutics | 0.3 | $1.2M | 1.0M | 1.16 | |
| Amylin Pharmaceuticals | 0.3 | $1.1M | 100k | 11.38 | |
| Trinity Biotech | 0.2 | $1.0M | 101k | 10.18 | |
| Affymax (AFFY) | 0.2 | $990k | 150k | 6.61 | |
| Vivus | 0.2 | $975k | 100k | 9.75 | |
| Solta Medical | 0.2 | $840k | 267k | 3.14 | |
| BioSante Pharmaceuticals | 0.1 | $325k | 650k | 0.50 | |
| Ampio Pharmaceuticals | 0.1 | $320k | 75k | 4.27 | |
| LeMaitre Vascular (LMAT) | 0.1 | $221k | 37k | 5.91 | |
| Unilife Corp cs | 0.0 | $187k | 60k | 3.12 | |
| Uroplasty | 0.0 | $121k | 28k | 4.26 | |
| Curis | 0.0 | $140k | 30k | 4.67 | |
| Senesco Technologies | 0.0 | $116k | 446k | 0.26 | |
| Clovis Oncology | 0.0 | $141k | 10k | 14.10 | |
| Allos Therapeutics | 0.0 | $71k | 50k | 1.42 | |
| Orexigen Therapeutics | 0.0 | $25k | 16k | 1.59 | |
| Kensey Nash Corporation | 0.0 | $58k | 3.0k | 19.33 | |
| MELA Sciences | 0.0 | $37k | 10k | 3.70 | |
| MAKO Surgical | 0.0 | $63k | 2.5k | 25.20 | |
| Angeion Corporation | 0.0 | $33k | 6.4k | 5.19 | |
| Combimatrix Corporation *w exp 05/01/201 | 0.0 | $7.0k | 50k | 0.14 |
